XML 19 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated statements of loss and other comprehensive loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:      
Research and license revenue $ 19,391 $ 5,350 $ 3,747
Operating expenses:      
Research and development (40,105) (36,945) (15,701)
General and administrative (14,124) (12,018) (2,719)
Total operating expenses (54,229) (48,963) (18,420)
Operating loss (34,838) (43,613) (14,673)
Interest income (expense), net 257 (625) (342)
Foreign currency exchange gain (loss), net 2,923 2,040 (869)
Total non-operating income (loss) 3,180 1,415 (1,211)
Loss before income tax (31,658) (42,198) (15,884)
Income tax expense (249) (157) (43)
Loss for the year (31,907) (42,355) (15,927)
Foreign currency translation adjustment (6,749) (5,642) (202)
Total comprehensive loss $ (38,656) $ (47,997) $ (16,129)
Loss per share:      
Loss per share, basic $ (1.23) $ (2.14) $ (39.91)
Loss per share, diluted $ (1.23) $ (2.14) $ (39.91)
Weighted average common shares outstanding, basic 25,924,005 19,758,169 399,126
Weighted average common shares outstanding, diluted 25,924,005 19,758,169 399,126